Vista Pharmaceuticals Ltd.
BSE: VISTAPH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vista Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vista Pharmaceuticals is a Hyderabad-based company specialising in the formulation and manufacturing of pharmaceutical products, including antibiotics, anti-diabetics, and anti-hypertensives. The company focuses on supplying generic formulations to international markets, with a particular emphasis on the United States.
Business Model
The company operates as a niche player in the contract manufacturing and generic export segment, leveraging its USFDA-compliant manufacturing facilities. It generates revenue by producing and exporting various dosage forms, such as tablets, capsules, and liquids, to global markets.
Growth Outlook
Growth is primarily driven by the company's ability to maintain regulatory compliance with global health authorities to support its generic export strategy. The firm continues to focus on its niche position within the contract manufacturing sector to sustain its international market presence.
Key Risks
- Regulatory Compliance Risk. Failure to maintain USFDA or other global health authority approvals could severely restrict access to key international markets.
- Market Concentration Risk. Heavy reliance on the United States market exposes the company to fluctuations in American healthcare policy and generic pricing pressures.
- Competitive Intensity. As a small-scale player, the company faces significant competition from larger, well-capitalised pharmaceutical firms with greater economies of scale.
- Operational Risk. Dependence on a limited number of manufacturing facilities creates vulnerability to supply chain disruptions or production halts.
Start your research today
Unlock AI insights, financials, peers and live data on Vista Pharmaceuticals Ltd. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vista Pharmaceuticals Ltd.VISTAPH | ₹38 Cr | — | — | — | -271.0% | — | — | -37.2% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
Vista Pharmaceuticals Ltd.
BSE: VISTAPH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vista Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vista Pharmaceuticals is a Hyderabad-based company specialising in the formulation and manufacturing of pharmaceutical products, including antibiotics, anti-diabetics, and anti-hypertensives. The company focuses on supplying generic formulations to international markets, with a particular emphasis on the United States.
Business Model
The company operates as a niche player in the contract manufacturing and generic export segment, leveraging its USFDA-compliant manufacturing facilities. It generates revenue by producing and exporting various dosage forms, such as tablets, capsules, and liquids, to global markets.
Growth Outlook
Growth is primarily driven by the company's ability to maintain regulatory compliance with global health authorities to support its generic export strategy. The firm continues to focus on its niche position within the contract manufacturing sector to sustain its international market presence.
Key Risks
- Regulatory Compliance Risk. Failure to maintain USFDA or other global health authority approvals could severely restrict access to key international markets.
- Market Concentration Risk. Heavy reliance on the United States market exposes the company to fluctuations in American healthcare policy and generic pricing pressures.
- Competitive Intensity. As a small-scale player, the company faces significant competition from larger, well-capitalised pharmaceutical firms with greater economies of scale.
- Operational Risk. Dependence on a limited number of manufacturing facilities creates vulnerability to supply chain disruptions or production halts.
Start your research today
Unlock AI insights, financials, peers and live data on Vista Pharmaceuticals Ltd. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026